Trial Profile
Vaccination of Melanoma Patients (Stage II-IV) With ImmuFact IMP321, Tumor Antigenic Peptides and Montanide
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Eftilagimod alpha (Primary) ; Lymphocyte activation gene 3; Montanide ISA-51; Subunit vaccines
- Indications Malignant melanoma
- Focus Pharmacodynamics; Therapeutic Use
- 23 Oct 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 14 Oct 2014 Status changed from recruiting to discontinued due to low enrollment rate, as reported by ClinicalTrials.gov record.
- 19 Apr 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.